Table 1.
Characteristics of the primary study cohorts.
Fig 1.
Enrichment of endothelial cell transcripts in microvascular isolates.
The expression levels of selected endothelial cell markers and non-endothelial markers are expressed as fold change ratios relative to the levels of each transcript in bulk tissue homogenates.
Table 2.
Abbreviations, brief function and cell-type expression and expression levels of IRSP and endothelial cell transcripts in AD-tissue and vessels.
Fig 2.
Endothelial cell markers in parahippocampal gyrus bulk tissue.
Values represent relative log fold change in persons with AD relative to controls and log fold change in persons with AD and T2D who had been treated with anti-diabetes agents. * = p<0.05 after FDR correction; # = p<0.05 without FDR correction; ✦ = p<0.05 AD-No Treatment vs. AD-T2D Treatment.
Fig 3.
IRSP-associated markers in parahippocampal gyrus bulk tissue.
Values represent relative log fold change in persons with AD relative to controls and log fold change in in persons with AD and T2D who had been treated with anti-diabetes agents. * = p<0.05 after FDR correction; # = p<0.05 without FDR correction; ✦ = p<0.05 AD-No Treatment vs. AD-T2D Treatment.
Fig 4.
Endothelial cell markers in microvascular enriched isolates from the parahippocampal gyrus.
Values represent relative log fold change in persons with AD relative to controls and log fold change in persons with AD and T2D who had been treated with anti-diabetes agents. * = p<0.05 after FDR correction; # = p<0.05 without FDR correction; ✦ = p<0.05 AD-No Treatment vs. AD-T2D Treatment.
Fig 5.
IRSP-associated markers in microvascular enriched isolates from the parahippocampal gyrus.
Values represent relative log fold change in persons with AD relative to controls and log fold change in persons with AD and T2D who had been treated with anti-diabetes agents. * = p<0.05 after FDR correction; # = p<0.05 without FDR correction; ✦ = p<0.05 AD-No Treatment vs. AD-T2D Treatment.